The Board of Directors of Prostatype Genomics AB proposes for the Annual General Meeting to authorize the Board to decide on a rights issue to intensify the launch of the Prostatype® test
The Board of Directors of Prostatype Genomics AB (”Prostatype Genomics” or “the Company”) has today, the 2[nd] of May 2022, decided to propose that the upcoming Annual General Meeting resolves to authorize the Board to decide on a rights issue of units of initially approx. SEK 22.5 million before issue costs, followed by an additional approx. SEK 22.5 million referring to attached warrants (”the Rights Issue”). The general public is also suggested to have the possibility to subscribe in the Rights Issue. The initial part of the Rights Issue is to 100 percent covered by pre-subscription and